Trimeric OX40-immunoglobulin fusion protein and methods of use
Compositions including a trimeric OX-40 fusion protein are disclosed. Also disclosed are methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells involving administering to the mammal a composition comprising a trimeric OX-40 fusion protein and a pharmaceutically acceptable carrier.
1. A fusion polypeptide comprising in an N-terminal to C-terminal direction:
an immunoglobulin domain, wherein the immunoglobulin domain comprises an Fc domain;
a trimerization domain, wherein the trimerization domain comprises a coiled coil trimerization domain; and
a receptor binding domain, wherein the receptor binding domain is an OX-40 receptor binding domain,
and wherein the fusion polypeptide self-assembles into a trimeric fusion protein.
2. The fusion polypeptide of claim 1 , wherein the fusion protein is capable of binding to the OX-40 receptor and stimulating at least one OX-40 mediated activity.
3. The fusion polypeptide of claim 1 , wherein the OX-40 receptor binding domain comprises an extracellular domain of OX-40 ligand (OX-40L).
4. The fusion polypeptide of claim 3 , wherein the OX-40 mediated activity is CD4+ T cell proliferation.
5. The fusion polypeptide of claim 3 , wherein the OX-40 receptor binding domain comprises a polypeptide sequence at least 95% identical to the amino acid sequence set forth as SEQ ID NO: 2.
6. The fusion polypeptide of claim 1 , wherein the trimerization domain is a TRAF2 or a Matrilin-4 trimerization domain.
7. The fusion polypeptide of claim 6 , wherein the trimerization domain comprises a TRAF2 trimerization domain.
8. A multimeric fusion protein comprising a plurality of the fusion polypeptides of claim 1 .
9. The multimeric fusion protein of claim 8 , consisting of three or six fusion polypeptides.
10. A recombinant nucleic acid comprising a polynucleotide sequence that encodes the fusion polypeptide of claim 1 .
11. A composition comprising the fusion polypeptide of claim 1 , or a nucleic acid encoding the fusion polypeptide, and a pharmaceutically acceptable carrier.
12. A fusion polypeptide comprising in an N-terminal to C-terminal direction:
an immunoglobulin Fc domain comprising the amino acid sequence set forth as SEQ ID NO: 6;
a TRAF2 trimerization domain; and
an OX-40 receptor binding domain comprising the amino acid sequence set forth as SEQ ID NO: 2,
wherein the fusion polypeptide self-assembles into a trimeric fusion protein.
13. The fusion polypeptide of claim 12 , wherein the trimeric fusion protein consists of three or six fusion polypeptides.
14. A method of enhancing T-cell proliferation in a subject, the method comprising:
administering to a subject exposed to an antigen, a therapeutically effective amount of the fusion protein of claim 1 , thereby enhancing T-cell proliferation in response to the antigen by the subject.
15. The method of claim 14 , wherein the subject is a human subject.
16. The method of claim 14 , wherein the fusion protein comprises in an N-terminal to C-terminal direction:
a dimerization domain comprising an immunoglobulin Fc domain;
a TRAF2 trimerization domain; and
an OX-40 receptor binding domain comprises a polypeptide sequence at least 95% identical to the amino acid sequence set forth as SEQ ID NO: 2,
wherein the fusion polypeptide self-assembles into a trimeric fusion protein.
17. The method of claim 14 , wherein the subject is exposed to the antigen prior to administering the fusion protein or wherein subject is exposed to the antigen and administered the trimeric OX-40L fusion protein at the same time.
18. The fusion polypeptide of claim 7 , further comprising a signal sequence, a linker sequence, an amino acid tag, a label, or a polypeptide sequence that facilitates purification.
19. The fusion polypeptide of claim 1 , wherein the Fc domain comprises the amino acid sequence set forth as SEQ ID NO: 6.